Stay updated on Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 and removed the previous funding/operating status notice (Revision: v3.4.1).SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide funding notice was added and the page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedShow glossary is now available, and the page includes updated metadata such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0' along with 'No FEAR Act Data', replacing the previous entries 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed on the page.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a consolidated Locations section listing Florida, New Jersey, New York, and Pennsylvania, removed the separate state location subsections, and updated the page to revision v3.3.3 with the HHS Vulnerability Disclosure link removed.SummaryDifference0.6%

- Check85 days agoChange DetectedRevision: v3.3.2 updated from v3.3.1; this is a minor site version change with no impact on study content or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial page.